Innovent Biologics China Summit feedback: IBI363 readout, mazdutide ramp-up, and GLP-1 pipeline are the key catalysts

Overview

This report is Morgan Stanley's conference feedback on Innovent Biologics Inc (1801.HK) after its participation in China Summit 2026. The report focuses on the oncology pipeline of IBI363, the commercialization progress of mazdutide, and subsequent GLP-1-related programs, and includes a DCF valuation approach and the main upside and downside risks.

Core views

The core view is positive: the dose-escalation phase of first-line NSCLC/CRC for IBI363 has been completed, and the subsequent randomized study and ASCO or ESMO readout represent important clinical catalysts; mazdutide sales are trending well, and the company remains confident in its 2027 Rmb5bn sales contribution target; China's GLP-1 penetration is below 1%, implying significant room for volume growth once reimbursement coverage expands.

Analysis framework

The report combines conference feedback with management commentary to assess the investment case for Innovent Biologics by focusing on clinical development progress, timing of key academic conference data disclosures, commercial sales ramp-up, NRDL access, and pipeline advancement pace.

Methodology notes

• Valuation methodDiscounted cash flow

  DCF

  The base case in the report uses a discounted cash flow method, assuming a WACC of 8.8% and a perpetual growth rate of 3%.

• Research frameworkMorgan Stanley ModelWare

  model convention

  Unless otherwise noted, the relevant metrics are based on Morgan Stanley ModelWare.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Innovent Biologics Inc / 1801.HK

  research target

  Strengths

  It has multiple clinical and commercial pipelines including IBI363, mazdutide, IBI3032, and IBI3042, and management described mazdutide's sales momentum as good.

  Weaknesses

  Value realization depends heavily on clinical data, reimbursement access, and commercialization ramp-up, and some programs are still at an early stage or awaiting key data validation.

  Comparison

  The report discusses the company's performance mainly in the context of China's innovative drug sector and rising GLP-1 penetration, and does not provide a detailed peer financial comparison.

  Risks

  Clinical trial failure, intensifying fast-follow molecule competition, and more cautious approval standards from overseas regulators toward Chinese drugs.

• mazdutide

  commercial growth driver

  Strengths

  Monthly sales have continued to grow after launch, the company maintained its 2027 Rmb5bn sales contribution target, and broader reimbursement coverage could unlock more volume.

  Weaknesses

  GLP-1 penetration in China remains low, and the volume ramp depends on payment coverage and market education.

  Comparison

  The report highlights the benefit of a low-penetration GLP-1 base in China, but does not provide quantitative comparisons with competitors.

  Risks

  NRDL negotiations, pricing pressure, competitor entry, and sales ramp-up falling short of expectations.

• IBI363

  clinical catalyst

  Strengths

  The dose-escalation phase of first-line NSCLC/CRC has been completed, the standard-of-care comparator trial is underway, and the company is discussing a global phase 3 study for second-line IO-resistant non-squamous NSCLC with the FDA.

  Weaknesses

  Key efficacy and safety data still need to wait for conference disclosures and subsequent clinical validation.

  Comparison

  The report does not provide a detailed head-to-head comparison with similar therapies.

  Risks

  Data readouts underperforming expectations, or delays in global phase 3 initiation or the approval pathway.

Key data

• Report date2026-04-02The report cover shows April 2, 2026 07:17 AM GMT.
• IBI363 data timingASCO or ESMOFirst-line NSCLC/CRC data are expected to be disclosed at ASCO or ESMO this year, and longer follow-up second-line data are also expected to be disclosed at related conferences.
• mazdutide 2027 sales targetRmb5bnThe company reiterated its confidence in the 2027 sales contribution target.
• China GLP-1 penetration<1%The report believes that the low penetration base means expanded reimbursement coverage could support sales growth.
• IBI3032 early weight-loss dataabout 10% in 4 weeksThe company said the early cohort showed about 10% weight loss over 4 weeks, and initial data may be disclosed at ADA, EASD, or Obesity Week.
• WACC assumption8.8%DCF base case valuation assumption.
• Perpetual growth rate3%DCF base case valuation assumption.
• Historical target price130The chart lists a target price of 130 on 2026-03-03; the currency is not specified in the extracted text.

Impact & implications

For investors, the near-term focus is on IBI363 clinical data and regulatory communication progress, the medium-term focus is on revenue realization from mazdutide after NRDL inclusion and commercialization ramp-up, and the long-term focus is on whether the GLP-1 pipeline can establish differentiation and a sustainable product ladder. If key data are positive and commercialization ramps faster than expected, valuation support may strengthen; otherwise, clinical failure, rapid-follow competition, and tighter overseas regulatory scrutiny could weigh on expectations.

Risks

• Clinical trial failure.
• Intensifying fast-follow molecule competition.
• More cautious approval standards from overseas regulators toward Chinese drugs, which may lengthen the approval process.
• Mazdutide commercialization ramp-up or reimbursement expansion progressing more slowly than expected.
• Pipeline data disclosures coming in below market expectations.

What to watch

• The quality of IBI363 first-line NSCLC/CRC data disclosed at ASCO or ESMO.
• Longer follow-up IBI363 second-line data and progress in FDA discussions on the global phase 3 study.
• Monthly mazdutide sales trends, NRDL access, and sales changes after reimbursement coverage expands.
• Initial IBI3032 data at ADA, EASD, or Obesity Week.
• The timetable for IBI3042 entering human studies this year.